ADAPTDOSE™: AN INNOVATIVE PLATFORM THAT REDUCES PRODUCT DEVELOPMENT TIME AND COST BY 30% OR MORE

Abstract

Are you searching for ways to accelerate first-in-human and dose escalation studies? Do you believe you are wasting R&D resources at earlier stages of development by making customized dosage forms for a specific clinical study that may never be used for a commercial product? Are you trying to formulate combination products with known chemical interactions? Adare Pharma Solutions can increase the likelihood of leveraging the practical knowledge gained during early formulation efforts in later stages of development.
 

Introduction

Considering the effort required to bring new products to market, drug development scientists have significant concerns in balancing the development of robust formulations, costs, and time to clinical studies at earlier stages of clinical research. A common approach to attempt to limit the expenses of formulation development at Phase I and II is to create a simple oral liquid, an API powder in capsule or powder for constitution or injection. These formulations are often limited in stability or present challenges for bioavailability for the API. As a result, companies will develop another formulation for Phase II or III studies and commercial launch that have the desired dose, stability, and enhanced bioavailability.